Doug Drysdale
21763
team-member-template-default,single,single-team-member,postid-21763,stockholm-core-2.4,select-child-theme-ver-1.0.0,select-theme-ver-9.5,ajax_fade,page_not_loaded,smooth_scroll,,qode_menu_,qode-mobile-logo-set,wpb-js-composer js-comp-ver-6.10.0,vc_responsive

Doug Drysdale

DOUG DRYSDALE was the global head of M&A at Actavis, closing 15 transactions totaling approximately $1bn, doubling the size of the business during his tenure. Then, as founding CEO of Alvogen, he took company from inception to over $450mm of sales in 36 countries in five years. His career spans 28-years where he has spearheaded several hundred pharmaceutical and biotech transactions, a CNS development company, has brought low cost medicines to U.S. consumers, and has served as CEO of both private and public companies.